"SMARCB1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A component of the SWI-SNF CHROMATIN REMODELING complex that functions as a PROTEIN PHOSPHATASE 1 regulator and to stabilize CHROMATIN at PROMOTER REGIONS. It is important for regulating CELL PROLIFERATION and CELL DIFFERENTIATION. Mutations in the SMARCB1 gene are associated with malignant RHABDOID TUMORS.
Descriptor ID |
D000071796
|
MeSH Number(s) |
D12.776.260.716 D12.776.660.235.650 D12.776.664.235.900 D12.776.930.809
|
Concept/Terms |
SMARCB1 Protein- SMARCB1 Protein
- Integrase Interactor 1 Protein
- BAF47 Protein
- SNF5 Homolog Protein
- Swi-Snf-Related Matrix-Associated Actin-Dependent Regulator Of Chromatin Subfamily B Member 1
- Swi Snf Related Matrix Associated Actin Dependent Regulator Of Chromatin Subfamily B Member 1
- BRG1-Associated Factor 47 Protein
- BRG1 Associated Factor 47 Protein
|
Below are MeSH descriptors whose meaning is more general than "SMARCB1 Protein".
Below are MeSH descriptors whose meaning is more specific than "SMARCB1 Protein".
This graph shows the total number of publications written about "SMARCB1 Protein" by people in this website by year, and whether "SMARCB1 Protein" was a major or minor topic of these publications.
View timeline visualization
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 2 | 2 |
2001 | 0 | 1 | 1 |
2002 | 0 | 4 | 4 |
2003 | 0 | 1 | 1 |
2004 | 0 | 2 | 2 |
2005 | 0 | 4 | 4 |
2006 | 0 | 3 | 3 |
2007 | 0 | 6 | 6 |
2008 | 0 | 3 | 3 |
2009 | 0 | 8 | 8 |
2010 | 0 | 7 | 7 |
2011 | 0 | 4 | 4 |
2012 | 0 | 7 | 7 |
2013 | 0 | 6 | 6 |
2014 | 0 | 5 | 5 |
2015 | 0 | 5 | 5 |
2016 | 5 | 2 | 7 |
2017 | 5 | 1 | 6 |
2018 | 4 | 1 | 5 |
2019 | 2 | 2 | 4 |
2020 | 3 | 4 | 7 |
2021 | 0 | 2 | 2 |
2022 | 0 | 2 | 2 |
2023 | 0 | 3 | 3 |
Below are the most recent publications written about "SMARCB1 Protein" by people in Profiles.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Rhabdoid tumors in patients conceived following ART: is there an association? Hum Reprod. 2023 Oct 03; 38(10):2028-2038.
-
Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. Neoplasia. 2023 03; 37:100880.
-
ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance. Acta Neuropathol. 2022 06; 143(6):697-711.
-
Low-grade diffusely infiltrative tumour (LGDIT), SMARCB1-mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. Neuropathol Appl Neurobiol. 2022 06; 48(4):e12797.
-
SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma. Biosci Rep. 2022 01 28; 42(1).
-
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021 09 22; 6(18).
-
Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Mod Pathol. 2021 10; 34(10):1850-1859.
-
Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup. Brain Pathol. 2021 09; 31(5):e12967.
-
Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India. Ann Diagn Pathol. 2021 Feb; 50:151679.